Condiciones de salud que cúrcuma puede ayudar a apoyar.
Turmeric (Curcuma longa) contains curcumin, which has demonstrated clinical efficacy in reducing gut inflammation and abdominal discomfort in IBD and IBS contexts. Clinical reviews confirm turmeric as a botanical studied for IBS symptom management. It has been used in Ayurvedic and TCM traditions for digestive complaints for centuries.
A 2023 three-arm randomized clinical trial (n=206) comparing curcumin from turmeric to omeprazole in functional dyspepsia found similar reductions in dyspepsia scores including heartburn at 28 and 56 days. Curcumin's anti-inflammatory and antioxidant properties may reduce esophageal and gastric mucosal inflammation. Traditional use in Ayurvedic and Chinese medicine for digestive disorders including heartburn spans 4,000 years. High-dose concentrated supplements may increase acid secretion in some individuals.
Turmeric (Curcuma longa) contains curcumin and has anti-inflammatory and antibacterial properties evaluated in clinical studies for acne. A 2022 systematic review of herbal medicine for acne vulgaris (34 clinical trials, 1,753 participants) cited turmeric preparations in its evaluation. Multiple evidence reviews list turmeric/curcuminoids among plant-derived anti-acne nutraceuticals with antioxidant, anti-inflammatory, and antibacterial activity.
Curcumin, the principal bioactive polyphenol in turmeric (Curcuma longa), has demonstrated antioxidant activity in multiple human randomized controlled trials (RCTs) and meta-analyses. It measurably raises total antioxidant capacity (TAC), superoxide dismutase (SOD), catalase, and glutathione, while lowering the lipid-peroxidation marker malondialdehyde (MDA). The primary molecular mechanism is activation of the Keap1-Nrf2/ARE transcriptional pathway, which upregulates endogenous cytoprotective enzymes. Evidence is genuine but qualified by curcumin's poor oral bioavailability, which limits the translation of in-vitro findings to clinical practice.
Multiple RCTs and meta-analyses indicate curcumin supplementation significantly reduces anxiety symptoms. A 2024 meta-analysis of 8 RCTs (567 participants) found a pooled SMD of −1.56 (p<0.001) for anxiety reduction. A 2025 systematic review of 15 RCTs (1,123 participants) also reported significant anxiolytic effects (SMD: −0.22, p=0.01). Evidence strength is moderated by study heterogeneity and small sample sizes.
Turmeric (Curcuma longa), the botanical source of curcumin, has both traditional Ayurvedic use for vascular conditions and modern scientific evidence for improving endothelial function, reducing arterial inflammation, and decreasing oxidative stress relevant to atherosclerosis. Multiple clinical studies demonstrate that curcumin-standardized turmeric extract improves FMD and reduces carotid intima-media thickness.
Turmeric (Curcuma longa) rhizome contains curcuminoids, particularly curcumin, which inhibit NF-κB and COX-2 inflammatory pathways. Multiple RCTs and systematic reviews demonstrate consistent improvements in knee OA pain, stiffness, and function compared to placebo, with effects comparable to NSAIDs in some trials.
Turmeric (Curcuma longa) and its curcuminoids have documented anti-asthmatic effects through inhibition of NF-κB and MAPK inflammatory pathways, reduction of leukotriene synthesis, and suppression of Th2-mediated airway inflammation. Turmeric has traditional use in Ayurvedic and Traditional Chinese Medicine for respiratory complaints including asthma.
Turmeric (Curcuma longa) and its curcumin extracts have been studied in 31 RCTs across 10 autoimmune diseases, with demonstrated improvements in rheumatoid arthritis, ulcerative colitis, psoriasis, Crohn's disease, SLE, and multiple sclerosis. It modulates immune cells and key inflammatory pathways including NF-κB. Traditional Ayurvedic use for arthritis and inflammatory bowel conditions spans millennia.
Turmeric (Curcuma longa) and its active curcuminoid fraction have been studied in RCTs for low back pain, including a double-blind placebo-controlled trial showing significant superiority of a turmeric-Boswellia formulation over placebo for acute LBP (p<0.001 for pain at rest, movement, and pressure pain). Curcumin inhibits COX-2, iNOS, NF-κB, and LOX pathways involved in spinal inflammation.
Turmeric's active compound curcumin inhibits arachidonic acid metabolism, reducing prothrombotic TXA2 and exerting antiplatelet and anticoagulant effects. A 2017 PubMed review documented curcumin's antithrombotic, anticoagulant, and fibrinolytic properties with defined molecular mechanisms. Authoritative sources list turmeric among the most common blood-thinning supplements.
Clinical evidence from RCTs, including a 2025 Scientific Reports trial, demonstrates curcumin significantly reduces systolic and diastolic blood pressure, particularly in metabolically compromised individuals. Meta-analyses confirm directional antihypertensive effects, though results are somewhat conflicting across studies. Mechanisms involve endothelial protection and anti-inflammatory effects.
Substantial meta-analytic evidence from RCTs demonstrates that turmeric/curcumin supplementation significantly lowers fasting blood glucose and HbA1c in patients with type 2 diabetes and metabolic syndrome. One meta-analysis of 18 RCTs (1,382 T2D patients) found curcumin reduced FBG by −11.48 mg/dL and HbA1c by −0.54%. Effects on insulin resistance (HOMA-IR) are also reported.
Preclinical studies and limited clinical evidence suggest curcumin supports bone health by promoting osteoblast activity and inhibiting osteoclastogenesis. A small clinical study found a 7% improvement in bone density over 6 months with a curcumin phytosome supplement. A 2025 systematic review and meta-analysis of animal studies confirmed significant BMD improvements.
Clinical trials show curcumin supplementation significantly improves working memory and cognitive speed, particularly in older adults and those with metabolic impairment. A systematic review of clinical trials found curcumin associated with statistically significant improvements in cognitive performance and serum biomarkers across multiple populations. Effects on attention and processing speed are also reported.
Turmeric's active compound curcumin inhibits COX-2 and LOX inflammatory enzymes, reducing joint pain and inflammation. Multiple RCTs show curcumin matches NSAIDs for osteoarthritis pain relief. Podiatric sources and Dr. Andrew Weil specifically recommend turmeric for bunion pain. Traditional Ayurvedic use for musculoskeletal pain is well-documented.
Turmeric (and its active compound curcumin) is explicitly cited for bursitis by the Arthritis Foundation and ADAM medical encyclopedia. Curcumin inhibits COX-2, 5-LOX, and pro-inflammatory cytokines (TNF-α, IL-1β) via NF-κB suppression. A 2016 systematic review found 1,000 mg/day curcumin reduced OA pain comparably to NSAIDs. Ayurvedic use for inflammatory joint conditions spans centuries.
Turmeric (Curcuma longa) and its active curcuminoids demonstrate antifungal properties against Candida albicans in multiple in vitro studies, including activity against drug-resistant strains. Turmeric inhibits Candida biofilm formation and modulates virulence factors. Traditional Ayurvedic use for fungal and infectious conditions spans thousands of years.
Turmeric (Curcuma longa) and its active constituent curcumin have been shown in multiple in vitro studies to have definite antifungal properties against Candida albicans, with both fungistatic effects at lower concentrations and fungicidal effects at higher ones. Turmeric disrupts Candida biofilms and inhibits Candida virulence factors. It has a long traditional use in Ayurvedic medicine for infections.
Turmeric (Curcuma longa) rhizome contains curcuminoids (primarily curcumin, 2–5%) that inhibit NF-κB, COX-2, 5-LOX, and pro-inflammatory cytokines driving cartilage degradation in OA. A landmark comparative RCT (Kuptniratsaikul et al. 2014, n=367 knee OA patients) found turmeric extract equivalent to ibuprofen 1200 mg/day for knee pain relief. ESCEO guidelines include curcuminoids from turmeric as a recognized OA nutraceutical.
Meta-analyses of RCTs confirm turmeric/curcumin significantly reduces LDL-C and triglycerides while showing trends for HDL-C improvement in patients with cardiovascular risk factors. A 2017 Nutrition Journal meta-analysis of 7 RCTs (649 patients) found significant LDL-C reduction (SMD = −0.340). A 2025 RCT additionally confirmed LDL-C reduction and HDL-C increase.
Turmeric's principal bioactive, curcumin, has been extensively studied in human clinical trials for its anti-inflammatory effects. It targets key pro-inflammatory pathways—most notably NF-κB, JAK/STAT, and MAPK—and downregulates cytokines such as TNF-α, IL-6, and IL-1β. However, a 2019 systematic review and meta-analysis of 19 RCTs found no statistically significant reduction in circulating inflammatory markers (CRP, hsCRP, IL-6, TNF-α), and a 2023 GRADE-assessed meta-analysis found positive aggregate effects on the same markers, reflecting ongoing debate. Poor oral bioavailability is the primary factor limiting clinical translation.
Turmeric root (Curcuma longa) contains curcuminoids that reduce chronic pain through NF-κB and COX-2 inhibition. A randomized crossover clinical trial in adults with moderate chronic pain confirmed analgesic effects at dietary doses. A 2014 Cochrane review cited ginger and Boswellia alongside turmeric-derived compounds for OA benefit.
Turmeric (Curcuma longa) root contains curcuminoids that improve endothelial function, reduce arterial stiffness, inhibit platelet aggregation, and decrease vascular inflammation. Meta-analyses of RCTs confirm curcumin/turmeric supplementation improves flow-mediated dilation in subjects with metabolic syndrome. Turmeric has been used in Ayurvedic and TCM for 4,000+ years for circulatory and blood conditions.
Multiple clinical trials and systematic reviews demonstrate curcumin improves cognitive function in older adults, particularly working memory and cognitive speed. A meta-analysis of 6 RCTs (289 subjects) found significant cognitive improvement in older adults (SMD=0.33, p=0.02). Mechanisms include anti-neuroinflammatory, BDNF-upregulating, and amyloid-modulating properties relevant to Alzheimer's disease risk.
Multiple RCTs and a 2024 meta-analysis of 13 placebo-controlled trials demonstrate curcumin's efficacy as an adjunctive therapy for ulcerative colitis, improving clinical remission rates and clinical response. Curcumin is extensively studied in IBD and has a substantial evidence base for UC specifically. Typical use is as adjunct to mesalamine.
Curcumin has been evaluated as adjunctive therapy in Crohn's disease (CD) with emerging clinical evidence from RCTs, though the evidence base is smaller than for ulcerative colitis. Preclinical data strongly support anti-inflammatory mechanisms relevant to CD pathophysiology. Two RCTs specifically in CD have been conducted.
Turmeric (Curcuma) contains curcumin, an anti-melanogenic compound with tyrosinase inhibition and anti-inflammatory properties relevant to periorbital hyperpigmentation. A 2025 PMC-indexed clinical study included curcuma oily extract as an active in an eye serum achieving a 47.94% reduction in under-eye hyperpigmentation over 6 weeks. Traditional Ayurvedic medicine has historically used turmeric topically for skin brightening.
Multiple RCTs and several meta-analyses support curcumin as an adjunctive treatment for major depressive disorder (MDD), with significant reductions in depressive symptom scores. A 2025 meta-analysis of 15 RCTs (1,123 participants) found a significant effect on depressive symptoms (SMD: −0.65, p=0.01). Curcumin also has documented traditional use in Ayurvedic medicine for mood disorders.
Turmeric (Curcuma longa) and its active curcuminoids have been studied in RCTs for dermatitis, psoriasis, and pruritus. Clinical studies show anti-inflammatory effects via NF-κB and cytokine inhibition. A systematic review of 18 RCTs found Grade B evidence for psoriasis and pruritus. Radiation dermatitis is also an area of clinical investigation.
Turmeric (containing curcumin as its primary bioactive) was studied in a combined curcumin-Boswellia formulation clinical trial in SUDD patients, demonstrating significant pain reduction at 30 days. Curcumin inhibits TNF-α, an inflammatory cytokine directly associated with diverticular disease, and multiple diverticular disease protocols identify turmeric/curcumin as a relevant natural anti-inflammatory agent.
Turmeric contains curcumin, which has antioxidant and anti-inflammatory properties studied in atopic eczema. A cream with six medicinal herbs including turmeric decreased eczema symptoms in 150 AD patients after 4 weeks. A 2016 review of 10 studies found significant improvement in skin disease severity with curcumin/turmeric.
Curcumin has demonstrated beneficial effects on pathways involved in endometriosis in preclinical (animal and in vitro) studies, including reduction of inflammation, hormone balance modulation, and anti-proliferative effects on endometrial lesions. Human clinical evidence is currently limited; the relationship is primarily mechanistic and preclinical at this stage.
Turmeric (Curcuma longa) and its active curcuminoids have robust clinical evidence for improving joint pain and physical function in osteoarthritis. A 2021 BMJ Open Sport & Exercise Medicine review confirmed significant improvement in pain relief and physical function for knee OA. A 2025 network meta-analysis of 39 RCTs (4,599 KOA patients) ranked curcumin/turmeric among the supplements with significant functional benefits.
Turmeric (Curcuma longa) and its ar-turmerone-rich oil have demonstrated antifungal activity against dermatophytes, particularly Trichophyton rubrum, in vitro and in formulated creams. A PMC study confirmed that 6% w/w turmeric cream is effective against dermatophytes and suitable as an alternative antidermatophytic preparation. Traditional use for tinea and ringworm in Ayurvedic and Southeast Asian medicine is substantiated by this ethnopharmacological evidence.
Curcumin from turmeric (Curcuma longa) stimulates bile production, increases gallbladder motility, and demonstrates anti-lithogenic effects in multiple animal studies by reducing the cholesterol saturation index in bile. Traditional use for hepatobiliary complaints spans Ayurveda and Chinese medicine for over 2000 years.
Turmeric (Curcuma longa) and its active compound curcumin are used in Ayurvedic and TCM traditions to support liver and gallbladder health, with some scientific validation. Curcumin has been shown to stimulate bile production and promote gallbladder motility in animal and in vitro studies, potentially reducing cholesterol saturation in bile and gallstone formation risk. Life Extension and PubMed-indexed reviews list curcumin among natural interventions that may reduce gallstone formation by improving cholesterol and lipid metabolism.
Turmeric (Curcuma longa) and its principal active compound curcumin have demonstrated anti-H. pylori activity in vitro and anti-inflammatory gastric effects in animal and human studies. Turmeric extract was shown to inhibit 31 clinical H. pylori strains in a dose-dependent manner. Clinical studies show improvement in GERD/gastritis clinical scores.
Turmeric's active compound curcumin has been studied for gout. A small 2025 RCT (n=48 gout patients) found 1,000 mg curcumin/day for 12 weeks reduced uric acid levels, gout flares, and pain. Curcumin inhibits NLRP3 inflammasome and NF-κB, key mediators of gouty inflammation; in animal models, high-dose curcumin inhibits xanthine oxidase and upregulates ABCG2 urate excretion. Results from a separate RCT in asymptomatic hyperuricemia were not superior to placebo, indicating mixed evidence.
Clinical and pre-clinical evidence supports curcumin's efficacy in periodontal disease management through anti-inflammatory and antibacterial mechanisms against periodontopathogens. A 2025 PMC systematic review confirmed curcumin's positive effects on gingival inflammation. Curcumin is also used as an adjunctive local delivery agent in scaling and root planing.
Curcumin modulates gut microbiota composition, promoting beneficial bacteria while suppressing pathogenic strains, and enhances intestinal barrier function. A 2026 clinical trial in IBD patients using 16S rRNA sequencing found transient microbiota shifts with curcumin. Preclinical and emerging clinical evidence support a meaningful gut microbiome interaction.
Turmeric (Curcuma longa), through its bioactive curcumin, has direct peer-reviewed evidence for gut-brain axis modulation including restoration of gut tight junctions, reduction of gut and brain neuroinflammation, modulation of gut microbiota, and vagus nerve-mediated anti-inflammatory effects. A dedicated review in the Journal of Neurogastroenterology and Motility confirms its therapeutic implications for the gut-brain axis.
Turmeric (Curcuma longa) contains curcuminoids with potent anti-inflammatory and antioxidant properties relevant to aging. A PubMed review in Foods documents turmeric/curcumin's role in healthy aging and inflammation management. Human clinical trials confirm curcumin from turmeric reduces inflammatory biomarkers and improves cognitive markers in older adults.
Clinical and mechanistic evidence indicates curcumin can reduce BMI and support weight management through anti-inflammatory and metabolic effects, particularly in obese or metabolically dysregulated individuals. Studies suggest curcumin reduces lipogenesis enzyme activity and increases lipolytic enzyme activity. Effects are modest and best observed alongside lifestyle interventions.
Clinical trial and meta-analytic evidence supports curcumin's benefit for cardiovascular health markers, including reductions in LDL cholesterol, triglycerides, blood pressure, and inflammatory markers. A 2025 Nature Scientific Reports RCT in diabetic patients with ASCVD risk found curcumin significantly reduced SBP, DBP, LDL-C, and TNF-α while raising HDL-C. Traditional use in Ayurveda also supports heart-protective use.
Turmeric (Curcuma longa), via its active polyphenol curcumin, is studied for heavy metal detoxification through induction of Phase II detoxification enzymes, upregulation of GSH synthesis, and direct chelation of metal ions via its beta-diketone structure. Animal studies show curcumin reduces tissue accumulation of lead, mercury, and cadmium; human evidence supports GSH restoration.
Turmeric (Curcuma longa) supports hormone detoxification through its active compound curcumin, which enhances hepatic glucuronidation—the Phase II liver process for estrogen conjugation—and induces Nrf2-regulated Phase II detoxification enzymes. It is consistently listed among evidence-based nutrients supporting Phase II liver estrogen detoxification pathways alongside resveratrol, dandelion, and rosemary.
Turmeric contains curcumin, which inhibits tyrosinase and melanin synthesis, and has been reviewed in multiple systematic analyses as a natural depigmenting agent for hyperpigmentation and melasma. It also carries traditional use across South Asian and Ayurvedic medicine for skin brightening and evening of skin tone.
Clinical trials and a meta-analysis of RCTs indicate curcumin may improve IBS symptoms, likely via mucosal anti-inflammatory and gut microbiome-modulating effects. A PMC meta-analysis identified 3 eligible RCTs for inclusion with positive directional findings. Evidence is promising but limited in volume.
Turmeric (Curcuma longa) is the plant source of curcumin, with 13 placebo-controlled RCTs in IBD supporting its use, particularly in UC. As a whole herb, turmeric also contains essential oils, turmerones, and other curcuminoids with synergistic anti-inflammatory effects. A 2025 meta-analysis confirms significant efficacy in UC clinical remission.
Meta-analytic evidence from multiple RCTs demonstrates curcumin significantly reduces HOMA-IR (insulin resistance index) and fasting serum insulin in metabolically dysregulated individuals. A meta-analysis of 17 RCTs found HOMA-IR reduced by −1.01 (p=0.0008) and fasting serum insulin by −1.69 mU/L. Curcumin has been shown to increase insulin sensitivity in liver, muscle, and adipose tissue in multiple models.
Turmeric (Curcuma longa) and its active polyphenol curcumin are among the most studied natural renoprotective agents. Multiple PMC systematic reviews confirm protective effects in diabetic nephropathy, chemotherapy-induced nephrotoxicity, and ischemia-reperfusion injury via Nrf2 induction, NF-kB inhibition, antioxidant, and antifibrotic mechanisms. It is named in the 2018 PubMed kidney stone review as an effective antioxidant phytophenol for urolithiasis prevention.
Turmeric (Curcuma longa) and its primary bioactive, curcumin, are well-studied for nephroprotective effects, particularly in diabetic nephropathy and CKD. Curcumin reduces renal inflammation via NF-κB pathway inhibition and activates Nrf2 antioxidant defenses. Clinical data in diabetic nephropathy patients show improvements in creatinine, BUN, and proteinuria. Turmeric/curcumin is recommended by multiple kidney health frameworks as an anti-inflammatory kidney-supportive herb.
Curcumin strengthens intestinal barrier integrity by upregulating tight junction proteins (claudin, occludin, ZO-1) and reducing mucosal NF-κB-driven inflammation that causes gut permeability. Emerging clinical data and substantial preclinical evidence support curcumin's role in mitigating 'leaky gut.' Gut-accumulating pharmacokinetics favor local epithelial effects.
Turmeric (Curcuma longa) and its principal active constituent curcumin have documented neuroprotective, anti-neuroinflammatory, and antioxidant properties relevant to cognitive function. The PMC narrative review includes turmeric among 21 validated cognitive phytonutrients. RCTs show curcumin improves memory and attention in healthy older adults.
Turmeric's active constituent curcumin has been used in Ayurvedic medicine for liver diseases for centuries. Scientific evidence shows curcumin modulates NF-κB, TGF-β/Smad, and Nrf2 pathways relevant to hepatic inflammation, steatosis, and fibrosis. A meta-analysis of RCTs found curcumin significantly reduced AST and ALT in MAFLD patients. NIH LiverTox notes active evaluation for liver diseases, though rigorous clinical proof is still evolving.
Turmeric (Curcuma longa) contains curcumin, which modulates NF-κB inflammatory signaling relevant to asthma, COPD, and cystic fibrosis. Preclinical and some clinical evidence supports anti-inflammatory effects in airways. The PMC respiratory herbal review identifies curcumin for CFTR protein correction in cystic fibrosis.
Turmeric (Curcuma longa) is the botanical source of curcumin, which has direct clinical evidence for topical treatment of lactational mastitis in a human RCT showing significant symptom reduction within 72 hours. Animal and cell studies further demonstrate anti-inflammatory action in mammary tissue via NF-κB inhibition and cytokine suppression.
Turmeric (Curcuma longa) contains curcuminoids, with curcumin being the primary active constituent studied for memory and neuroprotection. A 2018 UCLA RCT found bioavailable curcumin improved memory by 28% and reduced brain amyloid/tau accumulation over 18 months. Traditional Ayurvedic medicine has used turmeric for cognitive health for centuries, and epidemiological evidence links Indian dietary turmeric consumption with lower Alzheimer's rates.
A 2023 double-blind RCT and 2025 systematic review of RCTs support curcumin (the active compound in turmeric) for reducing primary dysmenorrhea pain and PMS symptoms. The turmeric–boswellia–sesame combination showed 12.6 times better total pain relief than placebo. Curcumin inhibits COX/LOX pathways and modulates prostaglandin synthesis.
Curcumin, the principal bioactive of turmeric (Curcuma longa), has been evaluated in multiple randomized controlled trials (RCTs) and meta-analyses specifically in patients with metabolic syndrome (MetS). Pooled evidence shows significant improvements in fasting blood glucose, triglycerides, HDL-cholesterol, diastolic blood pressure, and waist circumference. Mechanistically, curcumin exerts anti-inflammatory and antioxidant effects and modulates insulin sensitivity, lipid metabolism, and nitric oxide pathways. Overall evidence quality is moderate; larger, methodologically rigorous trials are still needed.
Curcumin has demonstrated significant mitochondrial-protective effects via antioxidant and anti-apoptotic mechanisms in multiple biological models. PMC reviews confirm curcumin reduces oxidative stress-mediated mitochondrial dysfunction, preserves membrane potential, and activates PGC-1α/SIRT3 pathways. Most evidence is preclinical; limited human data exist.
Turmeric (Curcuma longa) and its primary compound curcumin have been validated in various studies as expectorants and potential bronchodilators with effects on respiratory and immune health. Animal studies show curcumin attenuates mucus hypersecretion in asthma models. Traditional Ayurvedic use of turmeric for mucus-associated cough and bronchial congestion is well-documented.
Turmeric (Curcuma longa) contains curcuminoids with both traditional Ayurvedic/TCM anti-inflammatory use and modern RCT evidence for reducing exercise-induced DOMS, CK, IL-6, and oxidative stress markers. Evidence parallels curcumin research due to shared curcuminoid content.
Turmeric (Curcuma longa), containing curcumin as its primary active polyphenol, is supported by multiple RCTs and a 2022 systematic review and meta-analysis demonstrating reductions in DOMS pain, creatine kinase, and inflammatory cytokines. It inhibits COX-2, NF-κB, and MAPK inflammatory signaling. Traditional use in Ayurveda and Traditional Chinese Medicine for musculoskeletal pain also predates modern research.
Curcumin exhibits documented neuroprotective properties including anti-neuroinflammatory, antioxidant, and BDNF-upregulating effects relevant to nervous system health. Clinical evidence supports its benefit in cognitive function, depression, and neuropsychiatric conditions. Multiple pathways relevant to neural protection have been validated in human studies.
Curcumin has demonstrated anti-nociceptive and nerve-protective effects in preclinical models of diabetic neuropathy, sciatic nerve injury, and chemotherapy-induced peripheral neuropathy. Turmeric bioactive compounds suppress glial activation and improve mitochondrial function in neuropathic pain models. Human clinical data are emerging but limited.
Turmeric's active compound curcumin disrupts microtubule assembly in Giardia lamblia trophozoites, damaging the parasite's ventral disk and flagella. In vitro studies also document activity against Plasmodium, Leishmania, and Toxoplasma; turmeric appears in traditional Ayurvedic antiparasitic protocols.
Curcumin has been evaluated for PCOS in RCTs with evidence suggesting benefit for insulin resistance, androgen levels, and inflammatory markers. A ClinicalTrials.gov-registered RCT (N=120) is actively evaluating curcumin for metabolic control, microbiota, and quality of life in PCOS. Literature is inconclusive but mechanistically and clinically supported.
Curcumin, the primary bioactive of turmeric, has extensive clinical evidence as an anti-inflammatory agent. It has been included in post-illness recovery protocols and studies for COVID-19, reducing inflammatory markers and supporting immune restoration. Traditional Ayurvedic use of turmeric in convalescence is millennia-old.
Turmeric (Curcuma longa) containing curcuminoids has anti-inflammatory properties supported by clinical evidence relevant to post-surgical recovery. Reviews in orthopaedic post-surgical nutrition identify turmeric-derived curcumin as a plant-based anti-inflammatory offering an NSAID-sparing effect in post-surgical recovery with favorable safety profiles.
Turmeric (Curcuma longa) is the source of curcumin and is included in post-viral recovery clinical protocols for its anti-inflammatory and immunomodulatory properties. A 2021 observational study of nutritional supplementation in post-COVID fatigue referenced turmeric-derived compounds. Post-viral recovery integrative protocols (Holistic Primary Care, 2023) include curcumin from turmeric as an anti-inflammatory component.
Turmeric and its active constituent curcumin are used in multiple traditional postpartum traditions for anti-inflammatory effects and wound healing. Clinical trial evidence (Bumrungpert 2018, Thailand RCT) found turmeric as part of a combination supplement increased breast milk volume by 103% at 4 weeks. NIH LactMed documents its traditional use and clinical safety in postpartum women.
Turmeric (Curcuma longa) has been clinically tested for plaque psoriasis via topical gels and oral supplementation. A randomized double-blind intraindividual trial found turmeric gel significantly more effective than placebo for PASI reduction. Evidence is substantially driven by its active constituent curcumin.
Turmeric contains curcumin, with documented anti-inflammatory and mast cell-modulating properties studied in chronic urticaria. Clinical trials involving Curcuma longa have shown promising results in reducing chronic urticaria symptoms per a 2025 Sage systematic review. Traditional Ayurvedic use for inflammatory skin rashes is extensive.
Turmeric (Curcuma longa) contains curcumin and other curcuminoids with potent anti-inflammatory actions relevant to RA, including inhibition of COX-2, NF-κB, and pro-inflammatory cytokines. Multiple RCTs and meta-analyses support its use for reducing RA pain, joint stiffness, and inflammatory markers. Used in Ayurveda for joint disease for centuries.
A 30-patient RCT using an Ayurvedic polyherbal oral formula containing turmeric (and licorice, gotu kola, and other herbs) produced a 40% reduction in facial redness in rosacea patients over 4 weeks versus placebo. Turmeric alone showed no significant effect, suggesting synergy. Reviewed in J Drugs Dermatol 2018 as a rosacea biologically-based therapy.
Turmeric (Curcuma longa), primarily through its curcumin content, has demonstrated anti-scarring effects by inhibiting TGF-β/Smad signaling, reducing fibroblast proliferation, and decreasing pathological collagen deposition in hypertrophic scars. It is cited in multiple systematic reviews of natural products for scar management.
Turmeric's active compound curcumin has demonstrated antinociceptive and neuroprotective effects in sciatic nerve injury models and has been studied for low back pain in clinical trials. Pre-clinical studies show curcumin reduces allodynia and hyperalgesia in sciatic nerve constriction models. A randomized double-blind placebo-controlled clinical trial found a Boswellia-curcumin combination significantly relieved chronic lower back pain.
Curcumin exhibits immunomodulatory actions relevant to allergic diseases, including modulation of mast cells, eosinophils, Th1/Th2 balance, and IgE responses. Preclinical studies show efficacy in models of allergic rhinitis, asthma, and food allergy. A Phase 2 RCT in moderate-to-severe asthmatics is registered. Human clinical evidence for seasonal allergic rhinitis specifically is limited.
Turmeric (Curcuma longa) rhizome contains curcuminoids that inhibit NF-κB, COX-2, and leukotriene pathways to reduce nasal mucosal inflammation and congestion. Murine allergic rhinitis models confirm reduction in nasal symptoms; traditional Ayurvedic use for respiratory and sinus ailments is millennia-old. It is identified in pharmacognosy literature as a plant traditionally used for nasal congestion treatment.
Clinical and mechanistic evidence shows curcumin can reduce skin aging signs including wrinkles and loss of firmness through NF-κB inhibition, MMP suppression, and antioxidant activity. A 2022 RCT (N=60) using combined oral and topical curcumin found an 11.2% improvement in skin firmness over 4 weeks. A 2025 Frontiers in Pharmacology review confirmed curcumin as an anti-photoaging agent.
Curcumin supports skin elasticity and collagen by upregulating type I collagen synthesis in dermal fibroblasts and simultaneously inhibiting collagen-degrading MMPs. Clinical data from a 2022 RCT demonstrated improved skin firmness with combined oral and topical curcumin. These effects are mechanistically linked to NF-κB inhibition and Nrf2 activation.
Turmeric contains curcumin and other curcuminoids with anti-inflammatory and antioxidant properties studied in musculoskeletal pain. It has a long Ayurvedic tradition of topical and oral use for sprains, bruises, and soft tissue trauma, and has been evaluated in combination studies for soft tissue injury.
Curcumin is documented to prevent UV-induced skin photoaging and inflammation through NF-κB inhibition, ROS scavenging, and suppression of UV-activated signaling pathways (EGFR-MAPK, NF-κB, Nrf2/ARE). A 2025 Frontiers in Pharmacology review confirmed curcumin as an anti-photoaging agent. In vitro and limited clinical data support protective effects against UV-induced oxidative damage.
Turmeric (containing curcumin) has potent anti-inflammatory properties and has been traditionally recommended for tonsillitis across Ayurvedic and traditional Asian medicine. Modern studies confirm curcumin inhibits NF-κB and reduces inflammatory cytokines relevant to tonsillar inflammation. ENT practitioners cite turmeric for reducing throat inflammation in tonsillitis, though no dedicated tonsillitis RCTs exist.
Turmeric (Curcuma longa) contains curcumin, a well-documented COX-2 and NF-κB inhibitor used in Ayurvedic medicine for centuries to relieve dental pain. A 2013 PMC review confirmed massaging aching teeth with roasted ground turmeric as a documented traditional practice supported by anti-inflammatory and antiseptic evidence. A 2025 systematic review ranked turmeric (curcumin) among the top phytotherapeutic analgesics for dental pain in 21 clinical studies.
Turmeric (Curcuma longa) and its primary bioactive curcumin have been shown in multiple meta-analyses of RCTs to reduce triglycerides, particularly in patients with NAFLD, T2D, and metabolic syndrome. Curcumin is the primary active compound responsible for TG-lowering via PPAR-alpha activation and SREBP-1c inhibition.
Curcumin, turmeric's active compound, has anti-inflammatory and anti-H. pylori properties relevant to peptic ulcers. An uncontrolled clinical study (600 mg five times daily) showed ulcer healing in 48% of patients at 4 weeks and 76% at 12 weeks. An RCT found curcumin adjunct therapy improved dyspepsia symptoms in peptic ulcer patients, though it did not enhance H. pylori eradication.
Turmeric (Curcuma longa) and its active compound curcumin have preclinical evidence supporting uterine health, specifically protection of the uterine myometrium against oxidative damage implicated in fibroid development, and anti-endometriotic activity in animal models. Turmeric also has traditional use in Indian Ayurvedic medicine for uterine and gynecological conditions.
Turmeric (Curcuma longa), the source of curcumin, has traditional use in Ayurvedic and Asian medicine for infectious and inflammatory conditions. Its primary active compound curcumin has demonstrated antiviral activity against multiple viruses and has been tested in clinical trials for COVID-19. Modern evidence supports the traditional use for viral immune support.
Turmeric (Curcuma longa) and its active compound curcumin have demonstrated hepatoprotective properties in preclinical and human studies. Johns Hopkins Medicine acknowledges turmeric extract has been shown to protect against liver injury. Curcumin's anti-inflammatory and antioxidant mechanisms support liver detoxification pathway function and bile production.
Turmeric (Curcuma longa) and its principal active constituent curcumin have extensive scientific evidence for wound healing, including multiple clinical trials. Turmeric accelerates healing by reducing inflammation, promoting collagen deposition, stimulating fibroblast migration, and enhancing granulation tissue formation.
Turmeric (Curcuma longa) has long been used in Ayurveda and traditional Asian medicine topically and orally for abscesses and infected skin lesions. Curcumin, its principal bioactive, demonstrates antimicrobial and anti-inflammatory activity in vitro, including against Staphylococcus aureus. No high-quality clinical trials specifically targeting abscess treatment exist; evidence remains primarily traditional with biologically plausible but unvalidated scientific support.
Turmeric (Curcuma longa) is a traditional Ayurvedic remedy used topically and orally for anal fissures and fistulas due to its anti-inflammatory, antimicrobial, and wound-healing properties attributed to curcumin. It is explicitly named in Ayurvedic treatment protocols for fissure-in-ano. A 2025 scoping review of 19 clinical trials found curcumin improved wound healing in 89% of studies.
Turmeric (Curcuma longa) has traditional use in Ayurveda and TCM for bronchitis and respiratory inflammation, supported by published anti-inflammatory evidence in bronchial tissue and inclusion in a 2026 Nutrients review of plants for RTIs. Medical News Today (2024, peer-reviewed) notes curcumin's anti-inflammatory properties but limited direct clinical trial evidence specifically for bronchitis.
Turmeric is used in Ayurvedic medicine for corns as a topical anti-inflammatory and antiseptic paste, with curcumin's well-established anti-inflammatory properties providing pharmacological plausibility. Traditional application involves a turmeric paste applied to the corn daily. No corn-specific clinical trials have been conducted, but it is listed consistently in Ayurvedic corn treatment protocols.
Turmeric (Curcuma longa) provides curcumin and related curcuminoids that inhibit 5-alpha reductase and NF-kB-mediated inflammation implicated in androgenetic alopecia. Turmeric has an extended traditional use in Ayurvedic and Southeast Asian medicine for scalp conditions and hair health. Direct human RCT evidence for hair loss specifically is limited.
Turmeric (Curcuma longa) has been used in Ayurvedic and traditional Chinese medicine for respiratory infections, lung congestion, and inflammatory chest conditions associated with pneumonia. Phytotherapy reviews cite turmeric for reducing lung inflammation and improving airway clearance. Active curcuminoids provide anti-inflammatory NF-κB inhibition relevant to pneumonia pathophysiology.
Turmeric's active compound curcumin inhibits NF-κB and pro-inflammatory cytokines relevant to sinus mucosal inflammation. It has been used in Ayurvedic medicine for respiratory and sinus conditions. Clinical studies in sinusitis specifically are limited; anti-inflammatory mechanisms provide biological plausibility.
Volver